» Articles » PMID: 32551240

Typhim Vi Immunization Assists to Discriminate Primary Antibody Responses in Hematological Malignancies

Overview
Journal MethodsX
Specialty Pathology
Date 2020 Jun 20
PMID 32551240
Authors
Affiliations
Soon will be listed here.
Abstract

Assessment of specific antibody (Ab) production to polysaccharide antigens is clinically relevant, identifying patients at risk for infection by encapsulated bacteria and thus enabling a more rigorous selection of patients that can benefit of immunoglobulin replacement therapy. Classically, the gold-standard test is the measurement of antibody production to pure polysaccharide pneumococcal (PPV) immunization. Several factors, including introduction of conjugate vaccination schedule, serotyping analysis, high baseline Ab levels, have hindered the evaluation of polysaccharide antigens. This is even more difficult in secondary immunodeficiencies (SID), where patients can show secondary responses despite lack of primary antibody responses and present with recurrent or severe infections. Assessment of specific Ab production to pure S polysaccharide (TV) immunization has been proposed as a complementary test to PPV, given its low seroprevalence. To set the optimal cut-off value for PPV and TV response in SID, we tested different biostatistical methodologies, including ROC analysis, Youden index, Union index and Closest-topleft in a cohort of 42 SID patients and 24 healthy controls. The statistically chosen cut-offs value pre-post TV Ab ratio was ≥5, (sensitivity of 90%, specificity of 100%) and a postvaccination TV concentration of 28.5 U/mL (sensitivity of 90%, specificity of 95%), showing relevant clinical correlate.

References
1.
Sanges S, Wallet F, Blondiaux N, Theis D, Verin I, Vachee A . Diagnosis of primary antibody and complement deficiencies in young adults after a first invasive bacterial infection. Clin Microbiol Infect. 2017; 23(8):576.e1-576.e5. DOI: 10.1016/j.cmi.2017.02.005. View

2.
Mikulska M, Cesaro S, de Lavallade H, Di Blasi R, Einarsdottir S, Gallo G . Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019; 19(6):e188-e199. DOI: 10.1016/S1473-3099(18)30601-7. View

3.
Janssen W, Bloem A, Vellekoop P, Driessen G, Boes M, van Montfrans J . Measurement of pneumococcal polysaccharide vaccine responses for immunodeficiency diagnostics: combined IgG responses compared to serotype specific IgG responses. J Clin Immunol. 2013; 34(1):3-6. DOI: 10.1007/s10875-013-9925-y. View

4.
Jin C, Gibani M, Moore M, Juel H, Jones E, Meiring J . Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet. 2017; 390(10111):2472-2480. PMC: 5720597. DOI: 10.1016/S0140-6736(17)32149-9. View

5.
Parikh S, Leis J, Chaffee K, Call T, Hanson C, Ding W . Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. Cancer. 2015; 121(17):2883-91. PMC: 4545721. DOI: 10.1002/cncr.29438. View